ViroGates

Västra Hamnen Corporate Finance Initiates Coverage of ViroGates

Del
ViroGates A/S (Nasdaq First North Growth Market Denmark: VIRO), who delivers blood test products, primarily for emergency departments in hospitals, today announces that Västra Hamnen Corporate Finance AB will initiate research coverage of ViroGates.

The research coverage is governed by an agreement made between ViroGates and Västra Hamnen Corporate Finance. The analysis comprises an independent review of the Company, its products, markets and competitors as well as a financial scenario that constitutes the basis of an estimated justified market capitalization of ViroGates.

In its initiation coverage report, Västra Hamnen Corporate Finance AB concludes:

“Our DCF model suggests a fair value range for the stock price of DKK 68.00 – DKK 100.50 given our current view of the risk and including only the Acute Care market in our model. We see potential for further valuation upgrades when the company has overcome certain risks and when it gets closer to addressing other market segments.”

The initiation coverage report is available at Västra Hamnen’s website and at ViroGates’ investor website click here

For additional information, please contact

CEO Jakob Knudsen
Tel. (+45) 2226 1355, Email:jk@virogates.com
ViroGates A/S - www.virogates.com

Certified Advisor

Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, Email:per.lonn@vhcorp.se

Information om ViroGates

ViroGates
ViroGates
Banevænget 13
3460 Birkerød

https://www.virogates.com/

ViroGates is an international medtech company developing and marketing prognostics products to improve patient care, reduce healthcare costs and empower clinical staff in the healthcare sector. Based on more than 600 clinical trials and studies, ViroGates’ suPARnostic® product range supports hospital professionals in making clinical decisions on hospitalization or discharge of acute care patients as well as detecting and assessing the severity of cardiovascular diseases, type 2 diabetes, cancer, etc. suPARnostic® TurbiLatex is available on Roche Diagnostics’ Cobas instruments and ViroGates works with partners to develop solutions for other platforms. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Germany, Spain, and France, while distributors serve other markets. www.virogates.com

Følg pressemeddelelser fra ViroGates

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra ViroGates

Webinar i forbindelse med den igangværende fortegningsemission i ViroGates med Stokk.io7.12.2023 15:13:36 CET | Pressemeddelelse

BIRKERØD, DANMARK – ViroGates’ fortegningsemission finder sted i perioden 30. november til 13. december 2023, hvor eksisterende aktionærer i kraft af tildelte tegningsretter kan købe nye aktier i forholdet 1:1. Nye investorer, som er interesserede i at købe aktier, har mulighed for at købe tegningsretter (Ticker ”VIRO T”) via deres bank. Udbuddet er på maksimalt DKK 15.077.282 før emissionsomkostninger ("Udbuddet"). I Udbuddet er der afgivet bindende tegningsforpligtelser op til DKK 7.309.274, svarende til ca. 48 procent af Udbuddet, fra tre eksisterende aktionærer og repræsentanter fra bestyrelse og direktion. Udbuddet blev godkendt på en ekstraordinær generalforsamling den 24. november 2023. ViroGates inviterer i forbindelse med emissionen til en online præsentation og Q&A for alle investorer. Det er allerede nu muligt at tilmelde sig webinaret, og der kan via tilmeldingslinket også stilles spørgsmål på forhånd. Det vil ligeså være muligt at stille spørgsmål på Q&A-siden mens webinar

SAVE-MORE study on the effect of suPARnostic® guided anakinra treatment in patients with COVID-19 pneumonia published in Nature Medicine6.9.2021 15:25:56 CEST | Press release

BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today reports that Nature Medicine has published the previously announced positive results from the investigator-driven phase III SAVE-MORE study evaluating the effect of suPARnostic® guided anakinra plus standard of care treatment (SOC) in patients with moderate-to-severe COVID-19 pneumonia. The study demonstrated that patients triaged based on high suPAR results, that were subsequently treated with anakinra, in addition to current SOC, experienced reduced risk of death, ICU admission and increased the likelihood of full recovery. The study was conducted by the Hellenic Institute for the Study of Sepsis. KEY HIGHLIGHTS FROM THE STUDY Early triage with suPARnostic® for medical intervention using anakinra showed considerable efficacy and reduced risk of disease progression and death by 64 percent, according to day 28

ViroGates announces initial data on the use of suPARnostic® in the triaging of patients with COVID-19 symptoms1.5.2020 12:03:01 CEST | Pressemeddelelse

BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces that clinical researchers from the US, Greece and Denmark have disclosed the first clinical data on suPAR in patients affected by the novel coronavirus SARS-CoV-2.

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
HiddenA line styled icon from Orion Icon Library.Eye